Dasatinib (BMS-354825)

Name: Dasatinib (BMS-354825)
Brand: Selleck Chemicals
SKU: S1021
Rating: 5 (426 reviews)

For research use only.

Catalog No.S1021

426 publications

Dasatinib (BMS-354825) Chemical Structure

CAS No. 302962-49-8

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.

Selleck's Dasatinib (BMS-354825) has been cited by 426 publications

Nat Immunol, 2021, 10.1038/s41590-021-00948-8

PubMed: 34099917 ( click the link to review the publication )

Nature, 2020, 10.1038/s41586-020-2884-6

PubMed: 33149299 ( click the link to review the publication )

Science, 2020, 370(6513)eabc2754

PubMed: 33004676 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 10;S1934-5909(20)30144-2

PubMed: 32413332 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell, 2012, 21;151(7):1457-73.

PubMed: 23245941 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Acta Neuropathol, 2021, 10.1007/s00401-021-02327-x

PubMed: 34046693 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3705

PubMed: 34140493 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab538

PubMed: 34181735 ( click the link to review the publication )

EMBO J, 2021, e105770

PubMed: 33950519 ( click the link to review the publication )

J Immunother Cancer, 2021, 9(7)e002582

PubMed: 34326166 ( click the link to review the publication )

Theranostics, 2021, 11(4):1918-1936

PubMed: 33408789 ( click the link to review the publication )

Cancer Res, 2021, canres.0955.2021

PubMed: 34551960 ( click the link to review the publication )
EBioMedicine, 2021, 69:103457

PubMed: 34224975 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E361

PubMed: 33478100 ( click the link to review the publication )

PLoS Pathog, 2021, 17(8):e1009868

PubMed: 34415956 ( click the link to review the publication )

Cancers (Basel), 2021, 13(17)4262

PubMed: 34503072 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3635

PubMed: 34298852 ( click the link to review the publication )

Cell Death Dis, 2021, 12(9):827

PubMed: 34480020 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):139

PubMed: 34117218 ( click the link to review the publication )

FASEB J, 2021, 35(5):e21598

PubMed: 33871068 ( click the link to review the publication )

FASEB J, 2021, 35(1):e21229

PubMed: 33368613 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00400-1

PubMed: 34525344 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00396-2

PubMed: 34499862 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00303-2

PubMed: 34216546 ( click the link to review the publication )

Mol Oncol, 2021, 15(2):710-724

PubMed: 33155364 ( click the link to review the publication )

J Neuroinflammation, 2021, 18(1):18

PubMed: 33422097 ( click the link to review the publication )

Biochem Pharmacol, 2021, 192:114666

PubMed: 34186065 ( click the link to review the publication )

Mol Carcinog, 2021, 60(7):481-496

PubMed: 34018249 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Proteomics, 2021, 10.1002/pmic.202000251

PubMed: 34151541 ( click the link to review the publication )

J Pathol Clin Res, 2021, 10.1002/cjp2.211

PubMed: 33890726 ( click the link to review the publication )

Cardiovasc Toxicol, 2021, 10.1007/s12012-021-09672-z

PubMed: 34269955 ( click the link to review the publication )

Ann Hematol, 2021, 10.1007/s00277-020-04357-z

PubMed: 34110462 ( click the link to review the publication )

Environ Toxicol Pharmacol, 2021, 84:103625

PubMed: 33617955 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 571:174-180

PubMed: 34330061 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2021, 53(7):823-836

PubMed: 33961012 ( click the link to review the publication )
Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Cell Rep Med, 2021, 2(5):100267

PubMed: 34095877 ( click the link to review the publication )

eNeuro, 2021, ENEURO.0053-21.2021

PubMed: 33811086 ( click the link to review the publication )

Inflammation, 2021, 10.1007/s10753-020-01408-5

PubMed: 33527321 ( click the link to review the publication )

J Virol, 2021, JVI.00180-21

PubMed: 33597213 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)740

PubMed: 33578955 ( click the link to review the publication )

Gastroenterology, 2020, 159(3):956-968.e8

PubMed: 32485177 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(4):1879-1895

PubMed: 31874105 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5842

PubMed: 33203880 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, 30 pii: canres

PubMed: 32354737 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

Elife, 2020, 9e60470

PubMed: 33226337 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

Oncogene, 2020, 39(20):3980-3996

PubMed: 32238881 ( click the link to review the publication )

Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )
Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 39(2):308-321

PubMed: 31477830 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3869

PubMed: 33371412 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2730

PubMed: 32977582 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 31;12(4) pii: E841

PubMed: 32244515 ( click the link to review the publication )

Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Br J Haematol, 2020, 10.1111/bjh.17139

PubMed: 33216963 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):270

PubMed: 32631432 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(7):1004-1017

PubMed: 32238439 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30604-3

PubMed: 33333074 ( click the link to review the publication )
Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):20343

PubMed: 33230163 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16616

PubMed: 33024173 ( click the link to review the publication )

Sci Rep, 2020, 6;10(1):4211

PubMed: 32144278 ( click the link to review the publication )

Am J Pathol, 2020, S0002-9440(20)30550-2

PubMed: 33307038 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )

Cell Signal, 2020, 70:109574

PubMed: 32084531 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Blood Adv, 2020, 4(24):6106-6116

PubMed: 33351104 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )
Signal Transduct Target Ther, 2020, 5(1):139

PubMed: 32792487 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):145-154

PubMed: 32565942 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

J Clin Invest, 2020, 133310

PubMed: 32603316 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3416

PubMed: 32651372 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(8):e8849

PubMed: 31464373 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )
Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1945

PubMed: 31817360 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(4)E455

PubMed: 30987403 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

Pharmacol Res, 2019, 147:104357

PubMed: 31356863 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17104

PubMed: 31745115 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

J Acquir Immune Defic Syndr, 2019, 82(4):407-415

PubMed: 31658184 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )
Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Exp Hematol, 2019, 77:36-40.e2

PubMed: 31493432 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):4449-4456

PubMed: 31611954 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(9):1523-1534

PubMed: 31266784 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31405946 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Oncotarget, 2019, 10(31):2930-2946

PubMed: 31105876 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Am J Hum Genet, 2018, 103(6):976-983

PubMed: 30449416 ( click the link to review the publication )
Cell Rep, 2018, 25(13):3674-3692.e10

PubMed: 30590041 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3607-3618

PubMed: 30257219 ( click the link to review the publication )

Mol Cancer, 2018, 17(1):50

PubMed: 29455661 ( click the link to review the publication )

Elife, 2018, 7e33304

PubMed: 30231971 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(38):5221-5232

PubMed: 29849118 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(539)

PubMed: 30018082 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Front Immunol, 2018, 9:8

PubMed: 29403492 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Oral Oncol, 2018, 78:56-63

PubMed: 29496059 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

J Cell Sci, 2018, 131(22)jcs221788

PubMed: 30404826 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):584

PubMed: 29330550 ( click the link to review the publication )
Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1081

PubMed: 30319416 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cell Biol Int, 2018,

PubMed: 29885023 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6831-6838

PubMed: 29731862 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

J Pharmacokinet Pharmacodyn, 2018, 45(3):401-418

PubMed: 29446053 ( click the link to review the publication )

Oncotarget, 2018, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )
Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Leukemia, 2017, 31(5):1253-1254

PubMed: 28465516 ( click the link to review the publication )

Cancer Res, 2017,

PubMed: 27821486 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Int J Cancer, 2017, 140(5):1173-1185

PubMed: 27798955 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28638122 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Front Mol Neurosci, 2017, 10:418

PubMed: 29326548 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 28945796 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )
Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Exp Ther Med, 2017,

PubMed: 28810597 ( click the link to review the publication )

Oncotarget, 2017, 8(27):43662-43677

PubMed: 28599273 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Blood Adv, 2017, 1(26):2610-2623

PubMed: 29296914 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

EMBO Mol Med, 2016, 1;8(2):105-16

PubMed: 26758680 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )
Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Sci Signal, 2016, 9(456):ra116

PubMed: 27899526 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

Oncoimmunology, 2016, 5(12):e1240858

PubMed: 28123877 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1472-84

PubMed: 27364904 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(5):819-29

PubMed: 26883271 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Psychoneuroendocrinology, 2016, 66:138-49

PubMed: 26803529 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1862(11):2158-2167

PubMed: 27565738 ( click the link to review the publication )

Sci Rep, 2016, 6:26252

PubMed: 27188220 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45916-45925

PubMed: 27322141 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016, 7(17):24483-94

PubMed: 27016416 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )
Oncotarget, 2016,

PubMed: 27687593 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27602951 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27756880 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2015, 35(11):2326-35

PubMed: 26359510 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: 25248068 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2015, 56(9):5457-64

PubMed: 26284551 ( click the link to review the publication )
Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Exp Hematol, 2015,

PubMed: 25641047 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Oncogene, 2014,

PubMed: 23318431 ( click the link to review the publication )
Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1005

PubMed: 24434513 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Stem Cells, 2014, 32(9):2324-37

PubMed: 24806995 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 24196445 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Pharmacogenet Genomics, 2014, 24(1):52-61

PubMed: 24322003 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )
Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Proteomics, 2013, 13(23-24):3554-62

PubMed: 24167056 ( click the link to review the publication )

Cell Adh Migr, 2013, 7(4):362-9

PubMed: 23751956 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )
Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Oncotarget, 2012, 3(12):1557-65

PubMed: 23238683 ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	M3LadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIHNSnY4OiCq	M174[WROW09?	Ml\WTWM2OD1yLkCwNFA4KM7:TR?=	NF;oTmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m1OlA5OCd-MUe5OVYxQDB:L3G+
K562	NVe2VFBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGK5WnQ4OiCq	NELDO\|dFVVOR	MVfJR\|UxRTBwMECxJO69VQ>?	NXO2eYZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OVYxQDBpPkG3PVU3ODhyPD;hQi=>
M07e	NX7FO29ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlzsO\|IhcA>?	MmW0SG1UVw>?	M4fZPGlEPTB;MD6wNFEzKM7:TR?=	M4n5SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUW2NFgxLz5zN{m1OlA5ODxxYU6=
ALL3	M{\U[WN6fG:2b4jpZ{BCe3OjeR?=	MlzaNE4y\|ryP	NXHjNVZ6PzJiaB?=	NG\iXZBFVVOR	NFWzSHFKSzVyPUCuNFAxPCEQvF2=	NVTxcGx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4PFk2PDBpPkG5PFg6PTRyPD;hQi=>
CML	M1HFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3H6SFIxKG2rbh?=	NYfMNVdkTE2VTx?=	M3LmXGlEPTB;MD6wNFEh\|ryP	NULNZXZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyNVkxOTZpPkG5NlE6ODF4PD;hQi=>
BA/F3	MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUPMRVhwPzJiaB?=	NXm1cI1GTE2VTx?=	M4XSW2lEPTB;Nj61PFkh\|ryP	M3zWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEi4OlQ1Lz5{M{C4PFY1PDxxYU6=
BA/F3	NWW4TG43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIS4WZM4OiCq	M{i5[GROW09?	M2PVPWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh\|zszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB6OE[0OEc,OjNyOEi2OFQ9N2F-
BA/F3	Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWTqNmdTPzJiaB?=	NEP5VVFFVVOR	M{\MVGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1?	M2qx[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEi4OlQ1Lz5{M{C4PFY1PDxxYU6=
BA/F3	M{TYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF3xSHg4OiCq	MnvCSG1UVw>?	NEPsOlBKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2=	M{XOflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEi4OlQ1Lz5{M{C4PFY1PDxxYU6=
BA/F3	M33xWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVO3NkBp	NX21eoRXTE2VTx?=	M2DqR2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	NIHlfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1fwWFczKGh?	Mlq0SG1UVw>?	NIHMVGRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA{Os7:TR?=	M{XKclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|A{Lz5{M{OwNVcxOzxxYU6=
BA/F3	NXzRN3NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYPFTIxNPzJiaB?=	NGjEOVRFVVOR	Mk\CTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1?	M2m1SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|A{Lz5{M{OwNVcxOzxxYU6=
BA/F3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4jjZ\|czKGh?	NVfwZm5YTE2VTx?=	MVHJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVu3NkBp	M2XSNmROW09?	NHrtNolKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFAyO87:TR?=	NFP3bIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVcxOyd-MkOzNFE4ODN:L3G+
BA/F3	MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX7uW4w3PzJiaB?=	NXrBVVJITE2VTx?=	MWnJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO\|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=>	MoHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3NFMoRjJ\|M{CxO\|A{RC:jPh?=
BA/F3	NH7ndpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1vJfFczKGh?	M1;tc2ROW09?	MkfsTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1?	MlrVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3NFMoRjJ\|M{CxO\|A{RC:jPh?=
BA/F3	M3LUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1PZbFczKGh?	M33JXGROW09?	MkDjTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB\|LkdOwG0>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	NXTEWGh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWXmcpNUPzJiaB?=	NIT2OI5FVVOR	NGTaZXZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
T cell	M37tXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2\mflczKGh?	NU\3ZlR{TE2VTx?=	MVrJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=>	M12xOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUW0OVEzLz5zN{G1OFUyOjxxYU6=
WiDr	Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVe3NkBp	M4TUO2ROW09?	NULLRVg2UUN3ME2wMlA2OiEQvF2=	M2fU[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkG1OVEzLz5zNU[xOVUyOjxxYU6=
PC3	NXe1WWZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIjsdZo4OiCq	NWDFbYhDTE2VTx?=	MX3JR\|UxRTBwMEC5OEDPxE1?	NXG4codYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW2NVU2OTJpPkG1OlE2PTF{PD;hQi=>
MDA-MB-231	MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIjLRoc4OiCq	NIC5Z5NFVVOR	NWjESmY{UUN3ME2wMlAyOiEQvF2=	M2TYblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkG1OVEzLz5zNU[xOVUyOjxxYU6=
Hs578T	MVzDfZRwfG:6aXOgRZN{[Xl?		NIG2OFM4OiCq	M2HxUWROW09?	M3K3RWdKPTB;MD6wN{DPxE1?	NEfBVFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
HMEC	MkGwR5l1d3SxeHnjJGF{e2G7		NYHKN4tIPzJiaB?=	NWXsPIhDTE2VTx?=	NFHGcZZIUTVyPUGuPEDPxE1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
DU145	NEjGNYlEgXSxdH;4bYMhSXO\|YYm=		MnG0O\|IhcA>?	MXzEUXNQ	M4LwfWdKPTB;MD6xOkDPxE1?	NFqybWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
U251	NVzxcVE3S3m2b4TvfIlkKEG\|c3H5		M4jOeFczKGh?	NHzyd2FFVVOR	MY\HTVUxRTJwOEGg{txO	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
NCI60	NWX3O5pPS3m2b4TvfIlkKEG\|c3H5		NG\PWlg4OiCq	NEG1ZXRFVVOR	NVrISW1PT0l3ME21Mlch\|ryP	M{S2SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
MALME-3M	Mo[5R5l1d3SxeHnjJGF{e2G7		NWro[YViPzJiaB?=	M4H3bGROW09?	MYnHTVUxRTZwNkGg{txO	MlHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUWzNlcoRjJ2MEG1N\|I4RC:jPh?=
KM12	MlSwR5l1d3SxeHnjJGF{e2G7		NIDxbHo4OiCq	M1u2W2ROW09?	MUHHTVUxRTdwNESg{txO	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
SW620	M{\hdGN6fG:2b4jpZ{BCe3OjeR?=		NYfreGtCPzJiaB?=	NEDqWY1FVVOR	M{T2ZmdKPTB;OD60N{DPxE1?	MkLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUWzNlcoRjJ2MEG1N\|I4RC:jPh?=
RXF 393NL	NGnofYhEgXSxdH;4bYMhSXO\|YYm=		NGi3NZU1KGSjeYO=	MoLySG1UVw>?	NEjmSFZKSzVyPUCuNFIyPyEQvF2=	NUPJZppMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVMxPzRpPkKzNlU{ODd2PD;hQi=>
LXFA 983L	MU\DfZRwfG:6aXOgRZN{[Xl?		NUHQc5h6PCCmYYnz	MVXEUXNQ	M2PtZ2lEPTB;MD6wOVY2KM7:TR?=	MlfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUOwO\|QoRjJ\|MkWzNFc1RC:jPh?=
PRXF DU145	M3L0VWN6fG:2b4jpZ{BCe3OjeR?=		NIrmNHc1KGSjeYO=	M1m5TWROW09?	NEPGdZpKSzVyPUCuNFYzOyEQvF2=	NInyeYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1N\|A4PCd-MkOyOVMxPzR:L3G+
PAXF 1657L	M37pR2N6fG:2b4jpZ{BCe3OjeR?=		NGXK[Hk1KGSjeYO=	NX\FT49tTE2VTx?=	Mnu2TWM2OD1yLkGyNUDPxE1?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3M{C3OEc,OjN{NUOwO\|Q9N2F-
CXF 1103L	NXHyUGVWS3m2b4TvfIlkKEG\|c3H5		NX62WGJxPCCmYYnz	MlHHSG1UVw>?	M3:1Z2lEPTB;ND6zOkDPxE1?	Mk[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUOwO\|QoRjJ\|MkWzNFc1RC:jPh?=
GXF251L	MlfzR5l1d3SxeHnjJGF{e2G7		NVfodGRKPCCmYYnz	NITtXHRFVVOR	NV7ucmxXUUN3ME2yMlI2KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3M{C3OEc,OjN{NUOwO\|Q9N2F-
NCI-H23	NIfEco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4jGeFczKGh?	NGTwVFZFVVOR	MoDKTWM2OD1{LkK3JO69VQ>?	M1LjW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUKxNFIxLz5{M{WyNVAzODxxYU6=
HCT116	M3;2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVe3NkBp	NGHIZo1FVVOR	M2K5VGlEPTB;Mj6zJO69VQ>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV{MUCyNEc,OjN3MkGwNlA9N2F-
MCF7	NITWXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{DMelczKGh?	MV3EUXNQ	MVTJR\|UxRTJwNUeg{txO	NXS0d2VCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NlExOjBpPkKzOVIyODJyPD;hQi=>
NCI-H460	NGnmZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUG3NkBp	NIHtdXpFVVOR	MVPJR\|UxRThwOUmg{txO	NFrUbXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyNVAzOCd-MkO1NlExOjB:L3G+
DLD1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIO0bpo4OiCq	NYHIOI9ITE2VTx?=	M4jKd2lEPTB;ND62JO69VQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4N{m2NEc,OjN3Nke5OlA9N2F-
NCI-H661	NHXwc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml3DO\|IhcA>?	M3vzOGROW09?	NXjzU4h[UUN3ME23Mlgh\|ryP	M2\QeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[3PVYxLz5{M{W2O\|k3ODxxYU6=
A549	NYLMUFVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUS3NkBp	NH7mSllFVVOR	MVrJR\|UxRThwMjFOwG0>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4N{m2NEc,OjN3Nke5OlA9N2F-
U937	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY\uRVh4PzJiaB?=	Mn2ySG1UVw>?	MWrJR\|UxRTF{LkKg{txO	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4N{m2NEc,OjN3Nke5OlA9N2F-
HEK293	M4S2OmZ2dmO2aX;uJGF{e2G7	MWGxNOKh\|ryP		NXvRcYRtTE2VTx?=	NYDHWoZpUW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5ME[xNEc,OjJ5N{C2NVA9N2F-
HUVEC	MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6wMlE2yqEQvF2=	MmPsO\|IhcA>?	NHe2PJlFVVOR	NYjIWYZKUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO	MnW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NUO5PVMoRjJ{OEWzPVk{RC:jPh?=
HUVEC	NX7HU3MzTnWwY4Tpc44hSXO\|YYm=	MYKxOeKh\|ryP	NWTuSFJjPzJiaB?=	MX;EUXNQ	NVrj[nBMUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1?	NWTPSG5kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVM6QTNpPkKyPFU{QTl\|PD;hQi=>
Plasmodium falciparum	M1[3WGZ2dmO2aX;uJGF{e2G7	NIrxRo8yOMLizszN	NF[zZ\|kyPSCvaX6=	NEHXOo1FVVOR	NWXQZVliUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4\|ryP	NVrHPWQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVA{OzBpPkK0OVUxOzNyPD;hQi=>
PC3	M4DiS2Z2dmO2aX;uJGF{e2G7	MW[wMlEh\|ryP	M1W3NFUhcA>?	MmnRSG1UVw>?	MX7Jcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1?	NGXzN3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS2Nlk4PSd-MUm0OlI6PzV:L3G+
DU145	MortSpVv[3Srb36gRZN{[Xl?	MnH2NE4yKM7:TR?=	MWS1JIg>	NFz3OFJFVVOR	NV7Jd\|IzUW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0>	NFXE[lY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS2Nlk4PSd-MUm0OlI6PzV:L3G+
PC3	MVvLbY5ie2ViQYPzZZk>	M4W1UFAvOSEQvF2=	MVW1JIg>	MW\EUXNQ	M{DT[WlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=	M12zVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NE[yPVc2Lz5zOUS2Nlk4PTxxYU6=
DU145	M3LaeWtqdmG\|ZTDBd5NigQ>?	NXzsNJk5OC5zIN88US=>	NX6wcGN7PSCq	MoLlSG1UVw>?	MlH3TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N	NUizXZBORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlI6PzVpPkG5OFYzQTd3PD;hQi=>
PC3	NXrpRox4U2mwYYPlJGF{e2G7	MUCwMlEh\|ryP	M1rXcVUhcA>?	MnK4SG1UVw>?	MYPJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0>	NXXSbIlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlI6PzVpPkG5OFYzQTd3PD;hQi=>
DU145	NYfkZ4o3U2mwYYPlJGF{e2G7	M{mzflAvOSEQvF2=	MnfUOUBp	MnrlSG1UVw>?	M1nUNWlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P	M1XLO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NE[yPVc2Lz5zOUS2Nlk4PTxxYU6=
Huh7	MkT6RY51cX[rcnHsJGF{e2G7	MUKyMlUh\|ryP	NEmyWGs1KGSjeYO=	NXPF[JlxTE2VTx?=	MXHJcohq[mm2czD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1?	NGLx[3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFY4Pid-MUezOlA3PzZ:L3G+
C6/36	NWOxeIVYSW62aY\pdoFtKEG\|c3H5	MYSyMlUh\|ryP	MYK0JIRigXN?	NXfTbYRiTE2VTx?=	M1PRc2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN\|Yh[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1?	NV\4VXFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
U937	NUW0[lc2TnWwY4Tpc44hSXO\|YYm=	NYPQNZU5OSEQvF2=	NHrNRXoyKGh?	M3\Pc2ROW09?	NFX4cW5T\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?=	MmToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OESwPVkoRjF5Nki0NFk6RC:jPh?=
U937	M{KwXWZ2dmO2aX;uJGF{e2G7	NELIeJAyKM7:TR?=	NXTodJl6OSCq	MnW0SG1UVw>?	MnnhVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM>	NEHvcGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFA6QSd-MUe2PFQxQTl:L3G+
murine mast cell	M3e0UmZ2dmO2aX;uJGF{e2G7	M4jsblEh\|ryP	NXfCVVVtOjRiaB?=	NFHvRoxFVVOR	MV;Jcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>?	NF7hToQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFA6QSd-MUe2PFQxQTl:L3G+
FDC-P1	NFjS[\|dHfW6ldHnvckBie3OjeR?=		MmLmOFghcHK\|		MYnJR\|UxKD1iMD6wNFc1KM7:TR?=	MkL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNU[2PFkoRjJyMUW2Olg6RC:jPh?=
K562	MlXOR5l1d3SxeHnjbZR6KGG\|c3H5		MojDO\|IhcHK\|		NXyxVFRuUUN3MDC9JFEzNjh\|IN88US=>	NG\5VmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxO\|g4Pyd-MkKyNVc5Pzd:L3G+
U937	NXTTNW1JS3m2b4TvfIlkcXS7IHHzd4F6		NHrJNXo4OiCqcoO=		NUmzWVN1UUN3MDC9JFE{NjZ\|IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzN{i3O{c,OjJ{MUe4O\|c9N2F-
Sf21	NHq3XohHfW6ldHnvckBie3OjeR?=		NUnGPWg3PSCvaX7z		MVvJR\|UxKD1iMUCg{txO	Mn3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NkG2PFEoRjJ{OU[xOlgyRC:jPh?=
Ba/F3	NVzwNZdVTnWwY4Tpc44h[XO\|YYm=		NF3PVlAyKGi{		NIDxXoxKdmirYnn0bY9vKG:oIFLjdk1C[mxiVEOxOWkhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNVSVR3IHzleoVtKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NInkN5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNFgxPid-MkO2NFA5ODZ:L3G+
Ba/F3	NXH6PHV{TnWwY4Tpc44h[XO\|YYm=		M{[xT\|EhcHJ?		NHTxW3VKdmirYnn0bY9vKG:oIFLjdk1C[mxiVEOxOWkhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGNzc0xibHX2[Ywh[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M1PRZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCwPFA3Lz5{M{[wNFgxPjxxYU6=
Ba/F3	MUPGeY5kfGmxbjDhd5NigQ>?		NXnmUHNLOSCqch?=		Mn7CTY5pcWKrdHnvckBw\iCEY4KtRYJtKFR\|MUXJJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIIDoc5NxcG:{eXzheIlwdiC2cnHud4Zm[3SnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	M3nzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCwPFA3Lz5{M{[wNFgxPjxxYU6=
Sf9	M4P0b2Z2dmO2aX;uJIF{e2G7		MX[xOUB1dyB{MDDtbY5{		NGLGbnlKSzVyIE2gNVMvOSEQvF2=	NYGzfXl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OVYyODFpPkKzPVU3OTBzPD;hQi=>
Sf9	NVLieIJCTnWwY4Tpc44h[XO\|YYm=		MnrHNlAhdWmwcx?=		NFXNT\|dKSzVyIE2gNlcvOyEQvF2=	NEPTNHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m1OlExOSd-MkO5OVYyODF:L3G+
HMC-1.2	NUjXPYh6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				M1X5T2lEPTBiPTCwMlgzKM7:TR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByNESwPUc,OjVyMES0NFk9N2F-
RXF 393NL	NWTBeGNzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn;3OEBl[Xm\|		NFHseHRIUTVyIE2gNE4xOjF5IN88US=>	MojxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{[xPVUoRjJ3MEe2NVk2RC:jPh?=
LXFA 983L	NHXGRmlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWjjNXRQPCCmYYnz		MVfHTVUxKD1iMD6wOVY2KM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB5NkG5OUc,OjVyN{[xPVU9N2F-
PRXF DU145	MlHRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{Wze\|Qh\GG7cx?=		MVvHTVUxKD1iMD6wOlI{KM7:TR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB5NkG5OUc,OjVyN{[xPVU9N2F-
PAXF 1657L	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3HKV\|Qh\GG7cx?=		M172[2dKPTBiPTCwMlEzOSEQvF2=	NG\ZW4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3OlE6PSd-MkWwO\|YyQTV:L3G+
GXF251L	MnO3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXq0JIRigXN?		NV35VXllT0l3MDC9JFIvOjVizszN	MoLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{[xPVUoRjJ3MEe2NVk2RC:jPh?=
CXF 1103L	NWXxbpNVSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUW2TpZTPCCmYYnz		M3nYXmdKPTBiPTC0MlM3KM7:TR?=	NUe1fZhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|YyQTVpPkK1NFc3OTl3PD;hQi=>
SH-SY5Y	MoniRZBweHSxc3nzJIF{e2G7	MYCwMlEhfU1?	NXTNUGVPOjRiaILz		MmTJTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVSD3TXVV[KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kBpgXCxZHnwcI9q\CClZXzsd{BifCByLkGgeW0h[W[2ZYKgNlQhcHK\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiY4n0c4ZtfW:{aX3leJJ6	Mnu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2Nkm3O\|EoRjJ3NE[5O\|cyRC:jPh?=
ECRF24	M3rQR2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NGrhVlU4OiCqcoO=		NXzrR3FDUUN3MDC9JFUvPyEQvF2=	M3jEXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEG1NVUzLz5{NUixOVE2OjxxYU6=
A2780	NGXlbXFEgXSxdH;4bYNqfHliYYPzZZk>		Mn35O\|IhcHK\|		NIrifpFKSzVyIE2gPE44KM7:TR?=	MmroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUWxOVIoRjJ3OEG1NVUzRC:jPh?=
HEK293	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=		Mn6xO\|IhcHK\|		NX7pO5JkUUN3MDC9JFE1NjNizszN	NIfORZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixOVE2Oid-MkW4NVUyPTJ:L3G+
MDA-MB-231	NFT2VmREgXSxdH;4bYNqfHliYYPzZZk>		NF;nd5U4OiCqcoO=		Mke5TWM2OCB;IECuNVc5KM7:TR?=	NFvrSZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	MlfPRY51cWmwdnHzbZZmKGG\|c3H5	NEXIeHYxNjFidV2=	MYqyOEBpenN?		MWXBcpRqcW64YYPpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFAvOSC3TTDh[pRmeiB{NDDodpMh[nlidILhcpN4\WyuIHHzd4F6	Mk\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{WzNVcoRjJ3OEO1N\|E4RC:jPh?=
MDA-MB-231	MXXD[YxtKGO7Y3zlJIF{e2G7	NX[5foV[OC5\|IIXN	NGn6cpkzPCC2bzC0PEBpenN?		MX7D[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBifCByLkOgeW0h[W[2ZYKgNlQhfG9iNEigbJJ{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUOxO{c,OjV6M{WzNVc9N2F-
MDA-MB-231	NGLod\|hHfW6ldHnvckBie3OjeR?=	NUTub49VRjBwMEOgeW0>	Mk[3NlAhcHK\|		M4njTGlvcGmkaYTpc44hd2ZiU4LjJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIF\BT{BxcG:\|cHjvdplt[XSrb36gZZQhRjBwMEOgeW0h[W[2ZYKgNlAhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	Ml71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{WzNVcoRjJ3OEO1N\|E4RC:jPh?=
MDA-MB-231	NFXMdoFCdnSrbXnndoF1d3K7IHHzd4F6	M1vHbVAvODNidH:gNE4{KHWP	M{DL[VIxKGi{cx?=		Mn36RY51cW2rZ4LheI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOC5yMzD0c{AxNjNidV2gZYZ1\XJiMkCgbJJ{KGK7IIfveY5lKGinYXzpcoch[XO\|YYm=	NXnGS4x5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U{OTdpPkK1PFM2OzF5PD;hQi=>
MDA-MB-231	M365OmZ2dmO2aX;uJIF{e2G7	NGflU3ExNjByMTD0c{AyKHWP	NULRTGU6OjBiaILz		M3jGTmlvcGmkaYTpc44hd2ZiU4LjJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFAvODBzIITvJFEhfU1iYX\0[ZIhOjBiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NWfOcXM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U{OTdpPkK1PFM2OzF5PD;hQi=>
MDA-MB-231	NG\OcmpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MWq+NE4xOSC3TR?=	MV2xNkBl[Xm\|		NVrXSIdGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3;sc456KG[xcn3heIlwdiCjdDC+NE4xOSC3TTDh[pRmeiBzMjDkZZl{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNWKjc3XkJIF{e2G7	NWfOc4pXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U{OTdpPkK1PFM2OzF5PD;hQi=>
MDA-MB-231	NVfSR5diSW62aYT1cY9zKGG\|c3H5	MXW0NEBu\y:tZz;kZZk>	MoPGNVgh\GG7cx?=		M2DhZmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNieHXuc4dz[W[2ZXSgbY4hW0OLRDDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDC0NEBu\y:tZz;kZZkh[WSvaX7pd5RmemWmIH\vdkAyQCCmYYnzJI1m[XO3cnXkJIV3\XK7IEOg[IF6eyCmdYLpcoch[2:vcH;1coQh\G:\|aX7n	M2TCUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N\|E4Lz5{NUizOVMyPzxxYU6=
MDA-MB-231	MljQR5l1d3SxeHnjbZR6KGG\|c3H5		M165flQ5KGi{cx?=		MX3JR\|UxKD1iMT6xNkDPxE1?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh7OUOzNkc,OjV6OUmzN\|I9N2F-
MCF7	NYPTPWxNS3m2b4TvfIlkcXS7IHHzd4F6		NG\1epk1QCCqcoO=		NILkXplKSzVyIE2gPE4xPSEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh7OUOzNkc,OjV6OUmzN\|I9N2F-
HCC366	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHezfmE4OiCqcoO=		MmrJTWM2OCB;IECuNFI6KM7:TR?=	MlnmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUGzOlkoRjJ4MUmxN\|Y6RC:jPh?=
NCI-H2286	M1LYfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MnnRO\|IhcHK\|		NH3mTnlKSzVyIE2gNE4xOzJizszN	NEXURYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG5NVM3QSd-Mk[xPVE{Pjl:L3G+
K562	M2jsWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NF;0OZQ4OiCqcoO=		NXftXW56UUN3MDC9JFAvODBzIN88US=>	MoKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUWxN\|YoRjJ4MUm1NVM3RC:jPh?=
K562	M2ricGN6fG:2b4jpZ4l1gSCjc4PhfS=>				M3X2ZWlEPTBiPTCwMlA5KM7:TR?=	NGDVU\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2OFUxOyd-Mk[yOlQ2ODN:L3G+
IR-K562	NVGwdoM5S3m2b4TvfIlkcXS7IHHzd4F6				NYTWbHhWUUN3MDC9JFEvQSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ4NEWwN{c,OjZ{NkS1NFM9N2F-
THP1	MlfJR5l1d3SxeHnjbZR6KGG\|c3H5				MUfJR\|UxKD1iNjFOwG0>	M2X3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[0OVA{Lz5{NkK2OFUxOzxxYU6=
HEK293	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=				MWHDR\|UxKD1iMU[g{txO	NGfkbGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2OFUxOyd-Mk[yOlQ2ODN:L3G+
K562	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=		MmLUOFghcHK\|		M{OzNGlEPTBiPTCwMlQ2KM7:TR?=	M4PzZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEWxO\|czLz5{NkS1NVc4OjxxYU6=
K562	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Ml\zO\|IhcHK\|		MmfMS2k2OCB;IECuNFAxOyEQvF2=	MoXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	NUPlU3pHTnWwY4Tpc44h[XO\|YYm=		M{OycVczKGi{cx?=		M2nZbmdKPTBiPTCwMlAxODNizszN	M4Lmc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
KU812	M2K4ZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVO3NkBpenN?		NXjPNlFHT0l3MDC9JFAvODByMzFOwG0>	MontQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
MEG01	M1vKfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1izZ\|czKGi{cx?=		MWjHTVUxKD1iMD6wNFA{KM7:TR?=	NVHqe\|M1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NUPJNmJITnWwY4Tpc44h[XO\|YYm=		NUnTWoo{PzJiaILz		MXLHTVUxKD1iMD6wNFEh\|ryP	MoP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MkXVSpVv[3Srb36gZZN{[Xl?		NFzqelI4OiCqcoO=		MXLHTVUxKD1iMD6wNFEh\|ryP	NXy5cFBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NXjHe4lvTnWwY4Tpc44h[XO\|YYm=		MV63NkBpenN?		NG\3SYZIUTVyIE2gNE4xODFizszN	MkHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	M4OzbWZ2dmO2aX;uJIF{e2G7		M2jpe\|czKGi{cx?=		MlvES2k2OCB;IECuNFA{KM7:TR?=	NVfUeHBXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	MnHtSpVv[3Srb36gZZN{[Xl?		NX3sZVdWPzJiaILz		MYPHTVUxKD1iMD6wNFMh\|ryP	MkPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MYPGeY5kfGmxbjDhd5NigQ>?		M4jmelczKGi{cx?=		NYSySJNlT0l3MDC9JFAvODB\|IN88US=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NWLwTpEyTnWwY4Tpc44h[XO\|YYm=		M17SZ\|czKGi{cx?=		MUjHTVUxKD1iMD6wNFMh\|ryP	NFvLZ3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	NHTkO29HfW6ldHnvckBie3OjeR?=		MmG4O\|IhcHK\|		NGTIZ45IUTVyIE2gNE4xODRizszN	MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MmHqSpVv[3Srb36gZZN{[Xl?		M4DKdlczKGi{cx?=		MmrJS2k2OCB;IECuNFA1KM7:TR?=	NYK3cYJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NIfKdmFHfW6ldHnvckBie3OjeR?=		NWT0bpUzPzJiaILz		NVHINVFET0l3MDC9JFAvODB3IN88US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NW\MbmN3TnWwY4Tpc44h[XO\|YYm=		NFHpbm44OiCqcoO=		NIK2Wm1IUTVyIE2gNE4xODhizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NILKXolHfW6ldHnvckBie3OjeR?=		M3KyOFczKGi{cx?=		NX7DUmpMT0l3MDC9JFAvODB6IN88US=>	NWCycJV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NWTjSIFwTnWwY4Tpc44h[XO\|YYm=		MoLpO\|IhcHK\|		MVfHTVUxKD1iMD6wNUDPxE1?	NELoUXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	MYHGeY5kfGmxbjDhd5NigQ>?		NWHSfnNtPzJiaILz		M1znXGdKPTBiPTCwMlAyPCEQvF2=	NFXrOYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	M1fpWGZ2dmO2aX;uJIF{e2G7		NVm5U2JQPzJiaILz		M{nnPWdKPTBiPTCwMlAyPCEQvF2=	MnnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	M4nPc2Z2dmO2aX;uJIF{e2G7		Mn7wO\|IhcHK\|		MonrS2k2OCB;IECuNFE4KM7:TR?=	NGTlPIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	MlruSpVv[3Srb36gZZN{[Xl?		MnvSO\|IhcHK\|		NHLiSnVIUTVyIE2gNE4xOzlizszN	MkjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
CHL	NUX0R4szSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MkTrO\|IhcHK\|		NWDt[\|h3T0l3MDC9JFAvOjdizszN	NF\qVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
MOLM14	Mo\RRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MojRO\|IhcHK\|		Mm\TS2k2OCB;IEKuN{DPxE1?	NWmwPZN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	MWXGeY5kfGmxbjDhd5NigQ>?		Mo[4O\|IhcHK\|		MVLHTVUxKD1iMzFOwG0>	M2LkcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	MYrGeY5kfGmxbjDhd5NigQ>?		NXvvUZdsPzJiaILz		NVqyN\|A1T0l3MDC9JFMh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
MV4-11	M4\3Z2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUe5XGMyPzJiaILz		MVPHTVUxKD1iMz62JO69VQ>?	NHLEbXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
HEL	NIr3U2lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVy3NkBpenN?		NYXtUHpCT0l3MDC9JFUvOyEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NEH2flFHfW6ldHnvckBie3OjeR?=		NXzWc3pCPzJiaILz		MV\HTVUxKD1iOT65OEDPxE1?	NFH1W\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
KU812	MXjGeY5kfGmxbjDhd5NigQ>?	M{n0NFAvOSC3TR?=	NIDJeJgyKGi{		NHix[JNKdmirYnn0bY9vKG:oIFLDVk9CSkxiaX6gbJVu[W5iS2W4NVIh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhS3KtTDDwbI9{eGixconsZZRqd25iYYSgWFIxPyC\|aYTlJIF1KDBwMTD1UUBi\nSncjCxJIhzKGK7IHntcZVvd2Kub4T0bY5oKG2ndHjv[C=>	M3T1WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
KU812	MYTGeY5kfGmxbjDhd5NigQ>?	M4\KcFAvOSC3TR?=	M4DyOFEhcHJ?		NGDJVIFKdmirYnn0bY9vKG:oIFLDVk9CSkxiaX6gbJVu[W5iS2W4NVIh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhS3KtTDDwbI9{eGixconsZZRqd25iYYSgWFIxPyC\|aYTlJIF1KDBwMTD1UUBi\nSncjCxJIhzKGK7IHntcZVvd2Kub4T0bY5oKG2ndHjv[C=>	NX7yZ5dXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
MEG01	MV7GeY5kfGmxbjDhd5NigQ>?	M2nRcFAvOSC3TR?=	MmDvNUBpeg>?		NXvZU4dkUW6qaXLpeIlwdiCxZjDCR3IwSUKOIHnuJIh2dWGwIF3FS\|AyKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEO{a1ygdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODdic3n0[UBifCByLkGgeW0h[W[2ZYKgNUBpeiCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	M165[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
MEG01	NEnMU5lHfW6ldHnvckBie3OjeR?=	NUDTRVBkOC5zIIXN	NF3TOY0yKGi{		NHm3eHhKdmirYnn0bY9vKG:oIFLDVk9CSkxiaX6gbJVu[W5iTVXHNFEh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhS3KtTDDwbI9{eGixconsZZRqd25iYYSgWFIxPyC\|aYTlJIF1KDBwMTD1UUBi\nSncjCxJIhzKGK7IHntcZVvd2Kub4T0bY5oKG2ndHjv[C=>	NHu0TFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
K562	MWHGeY5kfGmxbjDhd5NigQ>?	M2HvS\|AvOSC3TR?=	MkXnNUBpeg>?		NFfsfmVKdmirYnn0bY9vKG:oIFLDVk9CSkxiaX6gbJVu[W5iS{W2NkBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	NVXwV2VCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
K562	MXjGeY5kfGmxbjDhd5NigQ>?	MX[wMlEhfU1?	NIKxVmsyKGi{		MlXSTY5pcWKrdHnvckBw\iCEQ2KvRWJNKGmwIHj1cYFvKEt3NkKgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gR5JsVCCyaH;zdIhwenmuYYTpc44h[XRiVEKwO{B{cXSnIHH0JFAvOSC3TTDh[pRmeiBzIHjyJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
K562	NYfTbZRTS3m2b4TvfIlkcXS7IHHzd4F6		MV[3NkBpenN?		M16ydGlEPTBiPTCwMlAxODJ3IN88US=>	NVr5[lN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NVQ5QTBpPkK2PFE1QDlyPD;hQi=>
BA/F3	M3TxVGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MofmO\|IhcHK\|		NE\Hd2NKSzVyIE2gNE4xQSEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjhzNEi5NEc,OjZ6MUS4PVA9N2F-
BAF3	NHvTcZdHfW6ldHnvckBie3OjeR?=		MXK3NkBpenN?		NF;KTHVGSzVyIE2gNE4xODByNDFOwG0>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
BAF3	MY\GeY5kfGmxbjDhd5NigQ>?		MVe3NkBpenN?		NUfrOok6TUN3MDC9JFAvODByMESg{txO	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
BxPC3	NEnZTlJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVy3NkBpenN?		M2fmWmVEPTBiPTCwMlA{OyEQvF2=	NF24ZZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CxNFgyOCd-MkewNVA5OTB:L3G+
MDA-MB-231	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NET2bm04OiCqcoO=		MkftSWM2OCB;IECuNFQ1KM7:TR?=	NH7VO3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CxNFgyOCd-MkewNVA5OTB:L3G+
Caki2	M1rNVWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGDjPWs4OiCqcoO=		Ml;pSWM2OCB;IECuNFU2KM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
NCI-H1975	NGfQUW9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmTFO\|IhcHK\|		Mm\vSWM2OCB;IECuNVc{KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
PC3	M4XqVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MUC3NkBpenN?		MVfFR\|UxKD1iMD6yN\|Ih\|ryP	NYG1XHpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNVA5OTBpPkK3NFExQDFyPD;hQi=>
insect	NVK5Z5BwTnWwY4Tpc44h[XO\|YYm=		NVPNUo5HOjBibXnudy=>		NFzLS2hKSzVyIE2gNE4xODB3IN88US=>	Mn;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUW4N\|UoRjJ5MUG1PFM2RC:jPh?=
MDA-MB-231	M{jMVWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXXmbpBEPSCmYYnz		NFXqcnpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEWg[IF6eyCkeTDQdoV{fG:EbIXlJIF{e2G7	NWDkZ28{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVU5OzVpPkK3NVE2QDN3PD;hQi=>
MDA-MB-231	M2n3SGZ2dmO2aX;uJIF{e2G7	M1zjZ\|MhfG9iMUCwJI5O	M2XWXlEvPSCqcoO=		MnTETY5pcWKrdHnvckBw\iCVUlOgdIhwe3Cqb4L5cIF1cW:wIHH0JJR6em:\|aX7lJFQyPiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG2IEOgeI8hOTByIH7NJJBz\WmwY4XiZZRm\CCob4KgNU42KGi{czDmc4xtd3enZDDifUB{\XK3bTDzeIlufWyjdHnvckBnd3JiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzNUizOUc,OjdzMUW4N\|U9N2F-
MDA-MB-231	MoLCSpVv[3Srb36gZZN{[Xl?	M1njdVMhfG9iMUCwJI5O	Mo[0NU42KGi{cx?=		NEi5TnRKdmirYnn0bY9vKG:oIF\BT{BxcG:\|cHjvdplt[XSrb36gZZQhfHm{b4PpcoUhQDZzIHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgN{B1dyBzMECgcm0heHKnaX7jeYJifGWmIH\vdkAyNjViaILzJIZwdGyxd3XkJIJ6KHOncoXtJJN1cW23bHH0bY9vKG[xcjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NEHLSoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxOVg{PSd-MkexNVU5OzV:L3G+
MDA-MB-231	NULhUVllSW62aX3p[5JifG:{eTDhd5NigQ>?	MXqxNEBvVQ>?	MV22JIhzew>?		NWfEXoY5SW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJI1wfGmuaYT5JIF1KDFyIH7NJIF1KDZiaILzJIJ6KG2rY4Lvd4NweHliYnHz[YQhe2O{YYTjbE14d3WwZDDj[YxtKG2rZ4LheIlwdiCjc4PhfS=>	MkfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUW4N\|UoRjJ5MUG1PFM2RC:jPh?=
MCF7	M{nMVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7	MUiwMlA{KHSxIEOwNEB2VQ>?	NXuyb3VvPSCmYYnz		M4fRd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[XRiMD6wN{B1dyB\|MECgeW0h[W[2ZYKgOUBl[Xm\|IHL5JHBz\XO2b1LseYUh[XO\|YYm=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzNUizOUc,OjdzMUW4N\|U9N2F-
HCT116	NV30dINLS3m2b4TvfIlkcXS7IHHzd4F6		M3fwclk3KGi{cx?=		M1TzV2lEPTBiPTC1MlI{KM7:TR?=	M3LFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1OFY1Lz5{N{G1OVQ3PDxxYU6=
A549	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=		Mn;SPVYhcHK\|		NXLGb3g4UUN3MDC9JFgvOzdizszN	NIXpXGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G1OVQ3PCd-MkexOVU1PjR:L3G+
U937	M4LLdGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MUC5OkBpenN?		MWjJR\|UxKD1iMUCuNlMh\|ryP	NXjudHo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexOVU1PjRpPkK3NVU2PDZ2PD;hQi=>
K562	M1LSfWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXvyOFNsQTZiaILz		MV\JR\|UxKD1iMUGuPVUh\|ryP	NY\rNm5ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexOVU1PjRpPkK3NVU2PDZ2PD;hQi=>
K562	MlvVR5l1d3SxeHnjbZR6KGG\|c3H5				MmXsR2M2OCB;IECuNlUh\|ryP	M1jaU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEe0PVE5Lz5{N{S3OFkyQDxxYU6=
K562	NH;hWXdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				MkPuS2k2OCB;IECuNFAyKM7:TR?=	Mlz1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{W1NlYoRjJ6NEO1OVI3RC:jPh?=
K562	Mn65SpVv[3Srb36gZZN{[Xl?				NHfRNlNKSzVyIE2gNE4xODByNkmg{txO	NV3oUFZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzPVU6PzNpPkK5N\|k2QTd\|PD;hQi=>
HL60	MVnGeY5kfGmxbjDhd5NigQ>?				NXHl[FBYUUN3MDC9JFAvODByMUGg{txO	NVOwe\|hJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzPVU6PzNpPkK5N\|k2QTd\|PD;hQi=>
KG1a	NVHITmR{TnWwY4Tpc44h[XO\|YYm=				M1PJO2lEPTBiPTC4Mlk5KM7:TR?=	NXz0Z5cyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzPVU6PzNpPkK5N\|k2QTd\|PD;hQi=>
B16-BL6	M{T3OmZ2dmO2aX;uJIF{e2G7	MoLKPE4yOyC3TR?=	NVvIbndkOjRidH:gOFghcHK\|		NF[3d\|BKdmirYnn0bY9vKG:oIHPlcIwhdWmpcnH0bY9vKG:oIH3veZNmKEJzNj3CUFYh[2WubIOgZZQhQC5zMzD1UUBqdmO3YnH0[YQh\m:{IEK0JJRwKDR6IHjyd{BjgSClZXzsJJdwfW6mIIPjdoF1[2hiYYPzZZk>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN7NUm3N{c,Ojl\|OUW5O\|M9N2F-
MCF7	M{XQPGZ2dmO2aX;uJIF{e2G7	NU\Hb4V[Py53IIXN	MU[xNEBl[Xm\|		MUHJcohq[mm2aX;uJI9nKGOxbH;ufUBnd3KvYYTpc44hcW5iaIXtZY4hVUOINzDj[YxteyCjdDC3MlUhfU1iaX7jeYJifGWmIH\vdkAyOCCmYYnzJIJ6KGO{eYP0ZYwhfmmxbHX0JJN1[WmwaX7nJIJie2WmIIDsZZRmKGOub37pcochfGW\|dB?=	NX\p[FViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzPVU6PzNpPkK5N\|k2QTd\|PD;hQi=>
U-2 OS	MX;xTHRUKGG\|c3H5				NGXmR2RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz	NF3uVJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NH3ze\|JyUFSVIHHzd4F6				MofwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	Mn7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NXPXXXZweUiWUzDhd5NigQ>?				NIr4OHByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	M3rRTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	M3zjbJFJXFNiYYPzZZk>				NUXlXGRWeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	M3:z[5FJXFNiYYPzZZk>				NVH5OXBWeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NHSwSHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MXHxTHRUKGG\|c3H5				NYm3cmU6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NIGybGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	M1;LU5FJXFNiYYPzZZk>				MlLUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgSGFQYSClZXzsdy=>	Mn\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MoLudWhVWyCjc4PhfS=>				MmmzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M1flPJFJXFNiYYPzZZk>				MkTVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	MkHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	NXL4SVRzeUiWUzDhd5NigQ>?				MmrOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	MXzxTHRUKGG\|c3H5				MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	MUjxTHRUKGG\|c3H5				MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	NH3tc4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	MVnxTHRUKGG\|c3H5				M2rSW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	M2CydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	M1jNR5FJXFNiYYPzZZk>				MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NXP5dGRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NHnCfmVyUFSVIHHzd4F6				NF76XFdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	NXTEe5Z2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	M3ezO5FJXFNiYYPzZZk>				MlrGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=>	NE\4W5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
HEK293	MVfGeY5kfGmxbjDhd5NigQ>?		NV\yU49pOSCqch?=		NXXzTYRrU2liPTCwMlAxODVizszN	MnzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEGxPVMoRjJ7OUSxNVk{RC:jPh?=
HEK293	MV3GeY5kfGmxbjDhd5NigQ>?		M4HrfFEhcHJ?		NGDxcIVKSzVyIE2gNE4xODZizszN	NVe3PJFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFEyQTNpPkK5PVQyOTl\|PD;hQi=>
Ba/F3	MlXSSpVv[3Srb36gZZN{[Xl?		NILUZZE1QCCqcoO=		MUDHTVUxKD1iMD6wNFAzOSEQvF2=	NH3zSVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGzO\|k5OSd-M{CxN\|c6QDF:L3G+
Ba/F3	NHS5ZYtHfW6ldHnvckBie3OjeR?=		MkTlOFghcHK\|		MlrzS2k2OCB;IECuNFAxOjVizszN	NXHOXHR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	NWLIN5ZPTnWwY4Tpc44h[XO\|YYm=		MVu0PEBpenN?		NUDKfGJoT0l3MDC9JFAvODByMkmg{txO	MlfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	MnPXSpVv[3Srb36gZZN{[Xl?		M4XKS\|Q5KGi{cx?=		MlSzS2k2OCB;IECuNFAxOyEQvF2=	NUfIPVBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	NXfZWYNiTnWwY4Tpc44h[XO\|YYm=		MVS0PEBpenN?		NU\lZmxCT0l3MDC9JFAvODByM{Og{txO	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF\|N{m4NUc,OzBzM{e5PFE9N2F-
Ba/F3	NX3jNG9FTnWwY4Tpc44h[XO\|YYm=		M4fBUFQ5KGi{cx?=		MmTqS2k2OCB;IECuNFAxPDJizszN	NVK0[3FLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	MUjGeY5kfGmxbjDhd5NigQ>?		MXO0PEBpenN?		NG[4colIUTVyIE2gNE4xODB5NzFOwG0>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF\|N{m4NUc,OzBzM{e5PFE9N2F-
Ba/F3	MYjGeY5kfGmxbjDhd5NigQ>?		NGLMdXc1QCCqcoO=		NFuxe3dIUTVyIE2gNE4xODB7ODFOwG0>	NXTVVlJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	NYDj[lh4TnWwY4Tpc44h[XO\|YYm=		MUi0PEBpenN?		NVT6NHZ2T0l3MDC9JFAvODBzNESg{txO	M1\oWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUO3PVgyLz5\|MEGzO\|k5OTxxYU6=
Ba/F3	NGjGNWhHfW6ldHnvckBie3OjeR?=		MlrNOFghcHK\|		NYTWdnMyT0l3MDC9JFIvPTZ{IN88US=>	NXTFT\|k1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Vero	Ml3TdWhVWyCjc4PhfS=>				M{POTHZmem9iY3XscJMhfmmjYnnsbZR6KHGKVGOg[o9zKFqra3GgeolzfXNiaX7obYJqfG:{cx?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OzJ{OUW0OUc,OzN{Mkm1OFU9N2F-
HepG2	MX3xTHRUKGG\|c3H5				MmHFTIVxTzJiY3XscJMhfmmjYnnsbZR6KHGKVGOg[o9zKFqra3GgeolzfXNiaX7obYJqfG:{cx?=	NXrzPWptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{OyNlk2PDVpPkOzNlI6PTR3PD;hQi=>
BV-173	MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TVcWlEPTB;MD6wNFAxODBzMEmg{txO	NIjD[nI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
K-562	NXPkcHBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXv5PYlrUUN3ME2wMlAxODByMEK2OkDPxE1?	NWHGc3J6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
BL-70	NGqzbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnLRm1sUUN3ME2wMlAxODByMEiyNkDPxE1?	NEfRWpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
EM-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPETWM2OD1yLkCwNFAxOTB6IN88US=>	M17qfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LAMA-84	M1m3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzkUXFjUUN3ME2wMlAxODByM{KxJO69VQ>?	NU\KdVNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MEG-01	NVXzeI5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfPO5RKSzVyPUCuNFAxODB7ODFOwG0>	NW\OdJl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
EoL-1-cell	M1zx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2Tve2lEPTB;MD6wNFAxOTNzIN88US=>	MnjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
CTV-1	NWq3[G9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrRN2hiUUN3ME2wMlAxODB2MESg{txO	M1XG[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TE-15	NWXXcWx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTBwMEC1PFkh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NOS-1	NYTkNoZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoiyTWM2OD1yLkCwOlE{KM7:TR?=	M1rzVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
D-336MG	Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwMEC2N{DPxE1?	M4PqclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LB1047-RCC	MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;HNnVKSzVyPUCuNFA6QDlizszN	M4W2c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LB996-RCC	NUnmO4hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLOb5hKSzVyPUCuNFA6QTFizszN	Moi1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SW982	NIDye29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXlTWM2OD1yLkCxNVE2KM7:TR?=	Mm\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TK10	M3L6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkT2TWM2OD1yLkCxNVc1KM7:TR?=	NH23bYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A704	NYnkU284T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXVdWRMUUN3ME2wMlAyPDlzIN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TE-8	M2jybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLjOnBKSzVyPUCuNFE2PzZizszN	MmPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
DOHH-2	NIXOVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTBwMEG3NVkh\|ryP	NVHuPXUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HOP-62	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLkTWM2OD1yLkCxPFM1KM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TE-12	NHzjS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M36wemlEPTB;MD6wNVg3OSEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KGN	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHuTWM2OD1yLkCxPVQzKM7:TR?=	NWPXWYJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H1648	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3f5bWlEPTB;MD6wNlAyOSEQvF2=	Mn\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
OS-RC-2	Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTUcWs5UUN3ME2wMlAzODNizszN	M{\YU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GB-1	MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHGTWM2OD1yLkCyNVU4KM7:TR?=	NWGz[FhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RXF393	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHflb3ZKSzVyPUCuNFI{PTdizszN	MmfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LC-2-ad	M{KyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\adnpPUUN3ME2wMlAzPTh4IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KS-1	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXKSpdKSzVyPUCuNFI4OyEQvF2=	MonjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ETK-1	NV72eJcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDFV3dKSzVyPUCuNFI5OzJizszN	MorZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SW954	M1y3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHuTWM2OD1yLkCyPVI4KM7:TR?=	M1vFTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
Becker	NXrSNI9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTBwMEOwNFMh\|ryP	M13aNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MZ1-PC	NHjJVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mof2TWM2OD1yLkCzNVE6KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
ES6	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrpNnRwUUN3ME2wMlA{OTl\|IN88US=>	NIK1RWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KURAMOCHI	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3mUpVjUUN3ME2wMlA{PDh5IN88US=>	MnvsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
CGTH-W-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DpWmlEPTB;MD6wN\|U1QCEQvF2=	NWmx[llxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
VA-ES-BJ	NXfFZWtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;RbFJXUUN3ME2wMlA{QTB{IN88US=>	NYK1bYNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LXF-289	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jDWmlEPTB;MD6wN\|k2PiEQvF2=	NGC1Xmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MPP-89	NUHnZXJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXr6[Jd5UUN3ME2wMlA1ODR7IN88US=>	NIXlOIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SW872	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3XZnpKSzVyPUCuNFQyPjFizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SNB75	NGrROGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmKyTWM2OD1yLkC0OFM2KM7:TR?=	M{LF[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
PSN1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvWTWM2OD1yLkC0OFc1KM7:TR?=	Mn3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LB831-BLC	NXn6e2I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTBwMES2NFkh\|ryP	M1HGWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MFH-ino	NYXFV\|hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPnZolSUUN3ME2wMlA1PzJ2IN88US=>	MlnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TGBC24TKB	NG\FSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPi[XJKSzVyPUCuNFQ4PjFizszN	NFXoeWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A388	NHrSOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrN[2xpUUN3ME2wMlA2ODl3IN88US=>	NVPhdohNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
BB30-HNC	Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;LN4JKSzVyPUCuNFU1OzdizszN	M1TPUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GI-ME-N	NVHKcWx1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\GfY9RUUN3ME2wMlA3OTF6IN88US=>	NGftXoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TGBC1TKB	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2i0emlEPTB;MD6wOlE3PCEQvF2=	NGnIc3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-10	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTBwME[zOVch\|ryP	M4W1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
A498	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4O4Z2lEPTB;MD6wO\|I5PCEQvF2=	M37uO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TE-11	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTBwMEe4OVgh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
BB65-RCC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XYcWlEPTB;MD6wPFIzPyEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
C2BBe1	NVzId4xqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUP0N5ZrUUN3ME2wMlA5OzB6IN88US=>	NHrkSZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H747	M{HjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnKyTWM2OD1yLkC4N\|YzKM7:TR?=	NHvmd4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
IST-MES1	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nzZWlEPTB;MD6wPFU2OiEQvF2=	M4\QZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KALS-1	M2XQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\2VVdKSzVyPUCuNFk1QSEQvF2=	M4HiXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GCIY	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDOTWM2OD1yLkC5OlU3KM7:TR?=	NUnrTWRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RL95-2	MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{GyU2lEPTB;MD6xNFM5KM7:TR?=	NV3HNIRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-1	NYnqXpVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTBwMUC1OEDPxE1?	MnPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H1355	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVT3XWQ6UUN3ME2wMlEyODJ6IN88US=>	NXjuVXZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SW962	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fCSmlEPTB;MD6xNVI6OiEQvF2=	MmOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KLE	M{HhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTkTXhxUUN3ME2wMlEyOzF5IN88US=>	M2T5WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MC116	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;zV\|BKSzVyPUCuNVE1OSEQvF2=	NV\qZ\|lTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NMC-G1	Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPBVWJGUUN3ME2wMlEyPjB4IN88US=>	NE\DZo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KU812	M1i0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTBwMUG4PFMh\|ryP	NU\NWXVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
COLO-829	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTlTZhKSzVyPUCuNVIzOTNizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NTERA-S-cl-D1	NHrs[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFuwfm1KSzVyPUCuNVIzQDNizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
IST-MEL1	NE\PR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PzbGlEPTB;MD6xN\|Q2KM7:TR?=	NVvOUlV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MLMA	NF\wdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13GZmlEPTB;MD6xOFA{OiEQvF2=	M1vkbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LS-123	MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnqV282UUN3ME2wMlE1ODZ2IN88US=>	M{W1fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LB2518-MEL	NFjCUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTBwMUSxOlIh\|ryP	NVi1cHB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NB69	M362OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\CNpNKSzVyPUCuNVQ1OzZizszN	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
8-MG-BA	M2DlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTBwMUW0OVgh\|ryP	Mn;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
K5	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTvRYZKSzVyPUCuNVY1QDlizszN	MnjiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KINGS-1	MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTiW\|BNUUN3ME2wMlE3PjZ4IN88US=>	M1nB[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SF268	NWLVSoJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1u5WWlEPTB;MD6xO\|QxPCEQvF2=	MkPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
PF-382	NW\zbWpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTBwMUe2O\|gh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SH-4	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1:zVWlEPTB;MD6xPFQyOyEQvF2=	MnrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NALM-6	M2TYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPkbmtYUUN3ME2wMlE6Ojl3IN88US=>	M1SxbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
CP66-MEL	NYO1e4VbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XZe2lEPTB;MD6xPVU{OSEQvF2=	Mlq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
697	NIizS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwMUm5PFch\|ryP	M2L5clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
CP67-MEL	NXnTT3JFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHMTWM2OD1yLkKwOFg5KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
DSH1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHGTWM2OD1yLkK0NFAyKM7:TR?=	NVL3VXN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HCE-4	M2\n[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrkTWM2OD1yLkK2OFM6KM7:TR?=	Mo\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MZ2-MEL	M3rS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3TPYF2UUN3ME2wMlI5PTN5IN88US=>	NE[2[\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BL-41	MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTBwMkmxNlMh\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HUTU-80	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTBwM{G0NkDPxE1?	M3X3fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LOXIMVI	M3v1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEewbGpKSzVyPUCuN\|E2ODNizszN	NIK2R4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
no-10	NHrISWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlriTWM2OD1yLkOxPVMyKM7:TR?=	NUDnZoF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KARPAS-422	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHZTWM2OD1yLkOzPVk4KM7:TR?=	M1K4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SW684	MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjFd2VKSzVyPUCuN\|Q6QCEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SF126	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3UV4R6UUN3ME2wMlM2PDFizszN	M4L5clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
D-263MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnFO3FKSzVyPUCuN\|YzOjRizszN	NIPpfFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
OVCAR-4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHMSXhKUUN3ME2wMlM4PDN\|IN88US=>	M4e2b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
BB49-HNC	NEflZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXi1epRWUUN3ME2wMlM5PTl7IN88US=>	Mo\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ONS-76	M2m2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLiWYNKSzVyPUCuOFI6PTFizszN	NIq3bZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MZ7-mel	NXfURXM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LqN2lEPTB;MD60O\|kyOSEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
RCC10RGB	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfxeoR{UUN3ME2wMlQ6OTFizszN	M4\hdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
BOKU	M3\WXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEH0dWNKSzVyPUCuOFkyOzNizszN	MmHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
no-11	M{O4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nSd2lEPTB;MD61NFIzQCEQvF2=	NGrjdWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
IST-SL2	NYjGe5U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzkd\|dKSzVyPUCuOVA{ODJizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
RKO	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonFTWM2OD1yLkWyPVY3KM7:TR?=	M1v0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HT-144	NF7DTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnz6TWM2OD1yLkWzOlA6KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H446	NELie4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPQTWM2OD1yLk[yO\|Yh\|ryP	NFq0Xoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
QIMR-WIL	NXSxOI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfqTZBEUUN3ME2wMlcxPjJ7IN88US=>	M3S3UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MHH-PREB-1	NUfkTGYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTBwN{S0Olkh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
EW-16	MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjtellKSzVyPUCuO\|YyPzhizszN	MkfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
EW-24	NWfYdXhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTBwN{ixOlUh\|ryP	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LB373-MEL-D	NHjkT\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3vdFhCUUN3ME2wMlgzPTB6IN88US=>	MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TE-9	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHDSI5KSzVyPUCuPFc2OzJizszN	M2Ti[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
A3-KAW	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXWdpFKSzVyPUCuPVg1PTJizszN	NYf5cGVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
A101D	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDLTI9ZUUN3ME2xMlA{ODR\|IN88US=>	NYi3O4pORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
OCUB-M	NGjhU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWP6fFBzUUN3ME2xMlA1PDF{IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
ES4	NVO3S5dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTFwMEWxOFUh\|ryP	NEGzTZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-6	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7CcWxKSzVyPUGuNlEzOjZizszN	NGHtN249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
D-502MG	M4q1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTFwMkOzO\|Yh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KNS-42	MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HjVmlEPTB;MT6yOFQyOiEQvF2=	M2P5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SNU-C2B	M3jhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWmzUm5[UUN3ME2xMlMxPTh7IN88US=>	M{fHeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H1838	M4fiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TjNWlEPTB;MT6zNFc{OyEQvF2=	M4\4fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NKM-1	M3v3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTFwM{C4OVkh\|ryP	M1PXUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GI-1	NH;LTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17OXmlEPTB;MT6zOlIzKM7:TR?=	MoTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NB5	M2mx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXudppbUUN3ME2xMlM6QDJ5IN88US=>	MkDpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
CAS-1	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInl[XZKSzVyPUGuOFA6QTJizszN	NYiwbJd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HCE-T	NWnnOZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTFwNU[3NVQh\|ryP	MlXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SBC-1	M4rxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\lOYRUUUN3ME2xMlU4QTh2IN88US=>	M4TnWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
JiyoyeP-2003	M1XNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\LXmlEPTB;MT63N\|Q3PiEQvF2=	Mm\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TE-5	M2rLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HkXGlEPTB;MT63PVE{QSEQvF2=	MmKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
CAN	M1fveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrWXIdKSzVyPUGuPFIzPTJizszN	M1;tNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SK-UT-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7nO5hKSzVyPUKuNVY3QTNizszN	NW\s[4ZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
JVM-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37wOGlEPTB;Mj6zOlI5PCEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LB771-HNC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLRfXBDUUN3ME2yMlU4PTVzIN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCCIT	MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzPNGhKSzVyPUKuPFY3OTZizszN	M{LmRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H2126	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLJSpR{UUN3ME2yMlg4PTV{IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
Calu-6	M{fLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTNwMEW3OFEh\|ryP	NWLOUIxZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SK-LMS-1	NV;LZWk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPjTWM2OD1\|LkGxPFg3KM7:TR?=	NIj3TZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
ARH-77	NEXPS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfiU5BkUUN3ME2zMlQ3QTF3IN88US=>	MoPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NB17	M4rK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmL2TWM2OD1\|Lk[zPFQ4KM7:TR?=	NWLiNmt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
A253	NVS2[213T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnxTWM2OD1\|LkezNlQ3KM7:TR?=	MnfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
OPM-2	NH7iNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTRwMke2PFUh\|ryP	M3;oelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MV-4-11	NEC1eppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHnOllKSzVyPUSuN\|Y1PTRizszN	NFO3c5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SR	NIPlTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\PTWM2OD12LkS5PVU1KM7:TR?=	Mn;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KG-1	NX\RTYxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHpdnVkUUN3ME20MlYxQDR3IN88US=>	M3TDR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
OCI-AML2	NHjBWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVW1WXBQUUN3ME21Mlg3OTV2IN88US=>	M{LHeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
D-247MG	NF7EeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXuTVBKSzVyPU[uNVI2OTlizszN	NHrTN4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
DJM-1	MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTZwNEi1OVgh\|ryP	Mn;JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
RPMI-6666	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTdwMkewOlch\|ryP	MlLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KARPAS-45	M37tU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3FZ4R5UUN3ME23MlUyPjdzIN88US=>	M{TFPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LP-1	M13Pe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTdwNUS3PFIh\|ryP	NWOxOlFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RS4-11	NWjw[Xh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTdwNkW3PFch\|ryP	MnjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
DU-4475	M4[0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NICwPFRKSzVyPUiuNlE3PTJizszN	NG\PZXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MONO-MAC-6	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHETWM2OD16LkK3NFY3KM7:TR?=	NF3OfVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-SNU-16	M33QPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRThwNU[xNlgh\|ryP	M2\0TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SJSA-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRThwN{K4NFUh\|ryP	NInvboc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MMAC-SF	NV\jNXc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M161NGlEPTB;OD63PVMxPyEQvF2=	M1T2SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SK-NEP-1	MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nBOmlEPTB;OD64PVE2PSEQvF2=	NFv5VHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrPVoFSUUN3ME24Mlk3PTJ7IN88US=>	M1z2dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SKM-1	M4LJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLMbWQ3UUN3ME25MlAyPzN2IN88US=>	MmfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LB2241-RCC	NYXLWYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLGVIM6UUN3ME25MlAzODF{IN88US=>	M{LvdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SIG-M5	NFu5W5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3f0fGlEPTB;OT6wNlQ6OyEQvF2=	NWS2d3dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
EVSA-T	NYX4[Xl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTlwMke3PVMh\|ryP	Mo\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
GT3TKB	NVLY[\|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUCwSGhRUUN3ME25MlM2PTR4IN88US=>	NGn6UWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NB6	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTlwOUKyOVkh\|ryP	M1e2S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EHEB	M3T1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXnTWM2OD1zMD6wOlU3KM7:TR?=	MlXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HEL	NYrvUHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXzXGRKSzVyPUGwMlQ4PzZizszN	NIrj[\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
ALL-PO	NFnNOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\w[lZKSzVyPUGwMlc6OzhizszN	M{\GflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TGW	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rTNGlEPTB;MUGuNlgzQCEQvF2=	Mo[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
BC-3	NUfmS4VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDLWlJKSzVyPUGyMlEyOzhizszN	Mnz3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
IA-LM	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnflTWM2OD1zMj60OFQ2KM7:TR?=	NXLyU4xjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
UACC-257	NYTw[\|hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXOcFFKSzVyPUGyMlkyQThizszN	NWnKTlNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KP-N-YS	NW\wU3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXCcIhrUUN3ME2xNk46Ojh\|IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
Raji	NHnaWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\mWIhKSzVyPUGzMlc1QTdizszN	M1vXPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SF539	NH7aXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHHTWM2OD1zMz64OVU4KM7:TR?=	MlPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
DMS-153	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvoTWM2OD1zND6wNFI5KM7:TR?=	M{DEdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
L-540	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jyOGlEPTB;MUWuNFY4OiEQvF2=	NYfMdo97RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MN-60	M2PNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LUc2lEPTB;MUWuNVk4QSEQvF2=	M4jlV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
RPMI-8866	M2SxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1K0T2lEPTB;MUeuOFQ2PCEQvF2=	MkL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H510A	M{fieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXFNGpKSzVyPUG5MlM6PzNizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NB13	NFfQR\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M323XGlEPTB;MUmuOFg4PyEQvF2=	M1\VdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HAL-01	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTF7Lke1OFMh\|ryP	NFLoSog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H720	M1nOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXITWM2OD1{MD6yO\|M{KM7:TR?=	NHLMSnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
REH	M1fs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;DTWM2OD1{MD62N\|U4KM7:TR?=	MnvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KNS-81-FD	NXflVYo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJ\|LkG0OkDPxE1?	NXnxNZhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HC-1	NUXHUm1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJ2LkW1OVEh\|ryP	NV7ifXVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H2141	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1K3NGlEPTB;MkSuO\|c2PCEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MOLT-4	NVrHXVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPKcoFKSzVyPUK2MlY4PTNizszN	M17S[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
OMC-1	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHyfnFKSzVyPUK3MlE1OjJizszN	M3H0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LC-1F	NHzyUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnFTWM2OD1{Nz6zNlQ2KM7:TR?=	MnXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H1304	NVva[nlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTJ6LkG2Nlgh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
BC-1	M4X1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvEdmF2UUN3ME2yPE43PTFizszN	M1qwOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H64	MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XiPGlEPTB;MkmuOlI2OyEQvF2=	M1jVbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MOLT-16	NUm3PY1QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHsO49KSzVyPUK5MlYzQTJizszN	NF;Jd2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
U-87-MG	NXzRNnV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDPcGN5UUN3ME2zNE44PjZizszN	NFq3fWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
GAK	M4XpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFi3c5dKSzVyPUOxMlI3QDZizszN	M4O0V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
ES8	MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\Fcm9KSzVyPUOyMlEzPTJizszN	NVS5T\|d2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HCC1599	M1r5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTN{LkOzNlUh\|ryP	NEL6dnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
EB-3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fTSWlEPTB;M{SuN\|EyPyEQvF2=	M2LUW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HCC1187	NFjD[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPocIVKSzVyPUO1MlgxPTJizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SK-PN-DW	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVKzZmVsUUN3ME2zOk4yQTR\|IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
JVM-3	NHLueGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\uc2lEPTB;M{euNlM{QCEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HCC2157	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTN5Lkm5OFYh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
A4-Fuk	MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jkbGlEPTB;M{iuNVAxQSEQvF2=	MkLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
COR-L279	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnITXdKSzVyPUSwMlI5PTFizszN	Mn3RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
DEL	M4noR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUL0e5J{UUN3ME20NU46ODh4IN88US=>	NH;R[JI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H1395	MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXH6fJlxUUN3ME20Nk4xOTZ\|IN88US=>	NInBWJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MHH-NB-11	M{S0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;lXlhZUUN3ME20N{4xQDF6IN88US=>	M3rKOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H2107	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzFfVJSUUN3ME20N{41QDR4IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NEC8	NXuxPYV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlH5TWM2OD12ND6zN\|Yh\|ryP	Ml:xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
COLO-684	NInzWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jzfWlEPTB;NE[uNlI2QCEQvF2=	NVPERYdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LS-411N	M2PuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTR6LkS3OFgh\|ryP	M2Wyb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23721490 20145167 23049975
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	31053734 26517812
ELISA	VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM). E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.	31110200 17684099

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib (BMS-354825) SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04933526	Not yet recruiting	Drug: Flumatinib\|Drug: Dasatinib	Chronic Myeloid Leukemia in Chronic Phase	Shenzhen Second People''s Hospital	July 1 2021	Phase 4
NCT04925648	Not yet recruiting	Drug: Dasatinib\|Drug: Darolutamide	Metastatic Prostate Cancer	St Vincent''s Hospital Sydney	July 1 2021	Phase 2
NCT04063124	Recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	February 14 2020	Phase 1\|Phase 2
NCT04155411	Recruiting	Drug: Dasatinib	Dasatinib\|BCR-ABL\|Chronic Myeloid Leukemia	Shenzhen Second People''s Hospital	December 1 2019	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
KX2-391 (Tirbanibulin)

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 (AGL 1872, EI 275) is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 (KIN001-112, KIN112, Dual LCK/SRC inhibitor) is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib (BMS-354825)